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Abstract 
We undertake an analysis of ongoing BC targeted therapy trials registered to CT.gov to describe patterns of ongo‑
ing clinical research, highlight gaps in current research programs and identify ways of optimizing ongoing initia‑
tives. A search of clinicaltrials.gov was conducted on September 4, 2013 to identify ongoing randomized phase II 
and III trials of targeted therapies in BC. A total of 280 trials were analyzed, the majority conducted in either human 
epidermal growth factor receptor 2 (HER2)‑positive (n = 79, 28.2 %) or hormone receptor (HR)‑positive (n = 104, 
37.1 %) populations. Less than half of all trials were conducted in populations selected to match the agent under 
investigation (n = 126, 45 %). HER2‑directed therapy is the single most investigated class of targeted agents (n = 73, 
26.1 %), but trials investigating anti‑angiogenic agents are also common (n = 49, 17.5 %). The most common new 
classes of agents under investigation in HR‑positive and triple negative (TN)/BRCA‑positive disease, are non‑receptor 
protein kinase‑inhibitors (n = 12; 11.5 %) and poly (ADP‑ribose) polymerase inhibitors (n = 6; 30 %), respectively. 
The majority of regimens combine new targeted agents with either chemotherapy (n = 164, 58.6 %) or endocrine 
therapy (n = 113, 40.4 %); a total of 8 trials (2.8 %) investigated peptide‑drug conjugates. The most frequently utilized 
end‑points were pathological complete response in the neo‑adjuvant setting (n = 36, 52.9 %) and time‑to‑event 
end‑points in the adjuvant and advanced settings (77.3 and 72.6 %, respectively). Our findings suggest a need for 
more target‑matched agent development, maintenance of a value‑based focus in research and a need for the clinical 
development of agents to treat TN/BRCA‑positive and HR‑positive BC.
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Background
Breast cancer (BC) is a significant health concern, with 
approximately 256,140 new diagnoses of BC in North 
America annually and 44,720 deaths in 2013 (DeSantis 
et  al. 2013; Canadian Cancer Society’s Steering Com-
mittee on Cancer Statistics 2013). Over 600 million dol-
lars are invested in BC research in the United States 
(US) each year by, the National Cancer Institute alone 
(National Cancer Institute 2013), and female BC has 
received the highest allotment of US national expendi-
ture for cancer treatment (National Cancer Institute 
2012). For over a decade, a main objective of BC research 
has been the development of targeted agents designed to 
improve outcomes while decreasing toxicity (Jain 2014). 
Efforts to move from a “one size fits all” to a more per-
sonalized approach to therapy have resulted in a substan-
tial, multi-faceted body of research. Examples of some 
of the more significant research gleanings related to trial 
populations, interventions and trial design are summa-
rized in Table 1. Prominent among these is the discovery 
of target-matched treatment strategies, the development 
of targeted treatments in populations enriched for the 
biological target of interest [e.g., hormone-receptor (HR) 
or human epidermal growth factor receptor 2 (HER2)]. 
Recent data show that wide-spread use of target-matched 
strategies over the last 15 years have resulted in dramatic 
improvements in the prognosis of patients with estrogen-
receptor (ER)-positive (Early Breast Cancer Trialists’ 
Collaborative Group 2005; Early Breast Cancer Trialists’ 
Open Access
*Correspondence:  sofia.torres@sunnybrook.ca 
1 Sunnybrook Health Sciences Centre, 2075 Bayview Ave., Room T2 023, 
Toronto, ON M4N 3M5, Canada
Full list of author information is available at the end of the article
Page 2 of 15Torres et al. SpringerPlus  (2016) 5:109 
Table 1 Lessons learned over the past decade of target-directed research in breast cancer
CT chemotherapy, ET endocrine therapy, FEC fluorouracil, epirubicin and cyclophosphamide, HER2 human epidermal growth factor receptor 2, HR hormone receptor, 
NAT neoadjuvant therapy, OS overall survival, pCR pathological complete response, T-D target-directed therapy, T-DM1 trastuzumab emtansine, TN triple negative
a Patient selection is based on over-expression, mutation or other modification of one or more biomarkers or on a multi-biomarker profile/signature with prognostic 
or predictive value
b Biomarker used to positively-select patients is targeted by the investigational T-D agent
c Depends on use of pCR as surrogate for survival (pCR translates to disease-free survival and overall survival according to results of the NOAH trial) (Gianni et al. 2013)
d Overall survival (or surrogate) as primary end-point
Lesson Examples
Trial populations
 Conduct trials in either positively‑
selecteda or target‑matchedb 
populations
Identification of 6 intrinsic biological BC subtypes (luminal A; luminal B; HER2‑enriched; basal‑like; normal 
breast‑like; and claudin‑low) (Perou et al. 2000; Sorlie et al. 2001; Carey et al. 2006; Prat et al. 2010)
Recurrence scores (e.g. OncotypeDX, PAM50, MammaPrint or IHC4) to help select patients that can forego 
adjuvant CT (Paik et al. 2006; Albain et al. 2010; Paik et al. 2004; Parker et al. 2009; Chia et al. 2012; Barton 
et al. 2012; Dowsett et al. 2008; Cuzick et al. 2011; van ‘t Veer et al. 2002; Cardoso et al. 2008; Rutgers et al. 
2011; van de Vijver et al. 2002)
Positive trial outcomes
HER2‑inhibitors in HER2‑positive populations (Slamon et al. 2001; Guan et al. 2013; Goldhirsch et al. 2013; 
Marty et al. 2005; Perez et al. 2011; Vogel et al. 2002)
ET in HR‑positive populations (Fisher et al. 1989; Early Breast Cancer Trialists’ Collaborative Group 2005)
Negative trial outcomes
Bevacizumab combinations in HER2‑negative populations (Miller et al. 2005, 2007; Miles et al. 2010; Robert 
et al. 2011; Brufsky et al. 2011)
Cetuximab combinations in non‑KRAS wild‑type (Carey et al. 2012; Baselga et al. 2010; O’Shaughnessy et al. 
2007)
Inaparib in triple‑negative populations (O’Shaughnessy et al. 2011a)
Interventions
 Consider combining T‑D with CT Trastuzumab plus CT (Goldhirsch et al. 2013; Marty et al. 2005; Perez et al. 2011; Slamon et al. 2001; Inoue 
et al. 2010; Swain et al. 2013) in HER2‑positive populations
T‑DM1 (Verma et al. 2012) in HER2‑positive populations
 Consider multi‑T‑D strategies based 
on a biological rationale
Everolimus plus ET in HR‑positive (Baselga et al. 2012b)
Dual HER2‑inhibition in HER2‑positive (Baselga et al. 2012c; Swain et al. 2013; Gianni et al. 2012)
 Consider continued T‑D therapy Early setting
Positive trial outcomes
Additional 5 years of tamoxifen (Davies et al. 2013; Gray et al. 2013) or letrozole (Goss et al. 2005) in HR‑
positive populations
Negative trial outcomes
An additional year of trastuzumab in HER2‑positive populations (Goldhirsch et al. 2013)
Advanced setting
Sequential ET in HR‑positive populations (Baselga et al. 2012b)
Continued HER2‑inhibition in HER2‑positive across multiple lines of therapy (Cameron et al. 2008; Verma et al. 
2012; von Minckwitz et al. 2009)
Trial design
 Consider the neo‑adjuvant setting as 
a platform for accelerated testingc
Pertuzumab (Gianni et al. 2012, 2015), trastuzumab plus FEC and paclitaxel (Buzdar et al. 2013) in HER2‑
positive NAT populations
Trastuzumab plus lapatinib (Baselga et al. 2012a; Robidoux et al. 2012) in HER2‑positive patient NAT popula‑
tions
 Utilize phase III trials to arrive at 
conclusive findings
Negative trial outcomes
Iniparib in TN populations (O’Shaughnessy et al. 2011a, b)
Positive trial outcomes
The majority of currently established T‑D agents (Baselga et al. 2012b, c; Buzdar et al. 1996, 1998; Cameron 
et al. 2008; Fisher et al. 1989; Slamon et al. 2001; The Nolvadex Adjuvant Trial Organisation 1985; Verma et al. 
2012)
 Are powered to assess improved 
survivald
Negative trial outcomes
Bevacizumab combinations in first‑line (Miles et al. 2010; Miller et al. 2007; Robert et al. 2011)
Positive trial outcomes
EGF104535 (Guan et al. 2013), CLEOPATRA (Swain et al. 2012; Verma et al. 2012), EMILIA (Baselga et al. 2012c; 
Swain et al. 2013)
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Collaborative Group 1998; Davies et al. 2011) and HER2-
positive disease (Dawood et al. 2010; Yin et al. 2011; Har-
ris et al. 2011), in both the early and advanced settings. 
Additionally, the discovery of 6 intrinsic biological BC 
subtypes (luminal A; luminal B; HER2-enriched; basal-
like; normal breast-like; and claudin-low) (Perou et  al. 
2000; Sorlie et al. 2001; Carey et al. 2006; Prat et al. 2010) 
has reshaped our understanding of disease biology and 
shifted our current approach to treatment. Treatment 
decisions are now guided by prognostic and predictive 
biomarkers [ER, progesterone receptor (PR) and HER2] 
which define 3 major therapeutic groups: HER2-posi-
tive disease (~20  % of all patients) (Arteaga et  al. 2012; 
Ross et al. 2009), HR-positive disease (~75 %) (Anderson 
et al. 2011; Lim et al. 2012; Nadji et al. 2005), and triple-
negative disease (TN, neither HER2, ER or PR-positive; 
~15 %) (Foulkes et al. 2010).
The National Institute of Health’s clinicaltrials.gov (CT.
gov) database is the most robust of international trial 
registries, serving as both a mandatory repository for 
information on clinical trials conducted under US regu-
lation and a prerequisite for publishing study results in 
peer-reviewed journals (Hirsch et  al. 2013). Although 
select data are populated by individual investigators and 
not always consistently reported, the database represents 
a unique resource through which to evaluate research. 
The database currently contains detailed information 
on more than 5000 clinical trials in BC from more than 
90 countries (ClinicalTrials.gov 2014b), and ranks BC 
among the most investigated tumor types per incidence 
(Hirsch et al. 2013). However, given that clinical research 
in oncology is both costly and associated with the highest 
rates of drug attrition and trial failure (Begley and Ellis 
2012; Hutchinson and Kirk 2011) we have undertaken 
an analysis of ongoing BC targeted therapy trials regis-
tered to CT.gov to describe patterns of ongoing clinical 
research, highlight gaps in current research programs 
and identify ways of optimizing ongoing initiatives.
Results
Study selection
A total of 1545 matching records were downloaded for 
analysis, and 1265 studies were excluded (Fig.  1). The 
remaining data set of 280 trials was locked and parsed to 
facilitate analysis.
Populations and classes under development
The majority of trials were conducted in either HER2-
positive (n  =  79, 28.2  %) or HR-positive (n  =  104, 
37.1  %) populations (Fig.  2a). Trials conducted in TN/
BRCA-positive disease accounted for 7.1  % (n =  20) of 
all research. Trials in all other populations accounted for 
27.5 % (n = 77) of research. Less than half of all ongoing 
trials were conducted in target-matched (i.e., enriched for 
the biological target of the therapy under investigation) 
populations (n = 126, 45.0 %; Table 2). The most inves-
tigated classes of agents were HER2-inhibitors (n =  73, 
26.1 %), endocrine agents (n = 52, 18.6 %) and anti-angi-
ogenic agents (n =  49, 17.5  %; Fig.  2b). The proportion 
of research dedicated to the development of emergent 
agents was only slightly greater than the proportion 
addressing established agents (52.5 and 47.5  %, respec-
tively), and consisted mostly of phase II studies (74.8 %).
Therapeutic strategies
The majority of regimens under investigation combined 
new targeted agents with either chemotherapy (n = 164, 
58.6  %) or endocrine therapy (ET, n  =  113, 40.4  %; 
Table 2). A total of 8 trials (2.8 %) investigated peptide-
drug conjugates, six trials assessed the HER2 antibody–
drug conjugate ado-trastuzumab-emtansine (T-DM1) 
in HER2-positive disease, one trial tested a luteiniz-
ing-hormone-releasing hormone receptor (LHRH-R)-
antibody conjugate in TN disease (LHRH-R-positive) 
and one investigated a glycoprotein NMB (GpNMB)-
directed conjugate in a population selected for GpNMB 
expression.
A broad range of therapeutic strategies were tested, 
with most trials investigating a single class of agents 
(mono-class, n  =  195, 69.6  %; Table  2), either used 
alone (single-targeted, n = 159, 81.5 %, with or without 
non-target-directed therapy; Fig.  3a) or in combination 
with agents from the same class (dual-targeted, n =  36, 
18.5  %). Of the trials investigating targeted combina-
tions from different classes (multi-class, n = 85, 30.4 %; 
Table  2), most combined two agents (dual-targeted, 
n = 78, 91.8 %; Fig. 3b) and others combined three agents 
(triple-targeted, n = 7, 8.2 %).
HER2‑positive
In HER2-positive disease, HER2-inhibitor trials made up 
81.0 % (n = 64) of ongoing research, while other research 
was directed toward anti-angiogenics (n  =  5, 6.3  %), 
mammalian target of rapamycin (mTOR)/phospho-
inositide 3-kinase (PI3K)/protein kinase B (Akt)-inhibi-
tors (n = 4, 5.1 %) and immunotherapy/vaccines (n = 4, 
5.1 %; Table 2). Mono-class trials (n = 60, 75.9 %; Fig. 3a) 
employed either a single HER2-inhibitor approach 
(n  =  39, 65.0  %) or a dual-HER2-inhibitor approach 
(n = 20, 33.3 %), with the exception of a single HER2 vac-
cine trial (n = 1, 1.6 %). Multi-class trials (n = 19, 24.1 %; 
Fig.  3b) were generally characterized by HER2-directed 
therapy combined with either anti-angiogenics (n  =  5, 
26.3 %), ET (n = 5, 26.3 %) or mTOR-inhibitors (n = 4, 
21.0  %). These trials included two conducted in HER2/
HR co-positive populations: one combining ET with a 
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dual HER2-blockade and another combining ET with a 
HER2-inhibitor and a HER2 vaccine.
HR‑positive
In HR-positive disease, ET made up 45.2  % (n  =  47; 
Table  2) of ongoing research, and 13.5  % was focused 
on mTOR/PI3K/Akt-inhibitors (n  =  14). Other classes 
under investigation in this area were intracellular, non-
receptor protein kinase (PK)-inhibitors (n = 12, 11.5 %) 
and growth factor-inhibitors (n  =  12, 11.5  %). Mono-
class trials (n = 51, 49.0 %; Fig. 3a) investigating ET ther-
apy (n = 44, 86.3 %) or mTOR pathway-inhibitor therapy 
(n = 3, 5.9 %) were common. Dual-targeted approaches 
combined traditional ET, such as tamoxifen- or aro-
matase-inhibitors with LHRH-R-agonists (n  =  10) or 
androgen receptor (AR)-targeted agents (n =  1). Multi-
class trials (n = 53, 51.0 %; Fig. 3b) commonly comprised 
ET in combination with either mTOR/PI3K-inhibitors 
(n = 10, 18.9 %), anti-angiogenics (n = 8, 15.1 %) or cyc-
lin-dependent kinase 4 and 6 (CDK4/6)-inhibitors (n = 4, 
7.5  %). A small number of trials also explored a triple-
targeted approach (n  =  5, 9.4  %), combining CDK4/6-
inhibitors plus mTOR/PI3K-inhibitors and ET (n  =  2), 
IGF(R)-inhibitors plus either a c-KIT- or mTOR-inhibitor 
and ET (n = 2), or a HER2-inhibitor plus metformin and 
ET (n = 1).
Total Records Idenfied: n=1,545
Key Search Terms: Breast  Cancer
Filters: Phase III OR Phase II (plus keyword “randomized”)
Database: ClinicalTrials.gov (All Time through Sep 4, 2013)
Current and Ongoing Studies
(Primary Compleon on or a­er Jan 2012): 
n=764
Randomized Trials of Target-Directed 
Therapy for BC: n=280
Exclude: n=158




Historical Trials eg. compleon before Jan 2012a
[“Primary Compleon Date” field]
Exclude: n=119 
Non-Systemic Therapy Trials 
e.g. behavioral, device, dietary, 










[based on manual review and veng]
Current and Ongoing Randomized Trials of Target-Directed Agents in BC
Exclude: n=47
Non-Therapeuc (Prevenon, 
Supporve and Diagnosc Studies)
[“Study Designs” field]
Phase III: n=116 Phase II: n=164
Fig. 1 PRISMA diagram representing screening process and final trial eligibility. aSome trial records did not have a primary completion date 
(n = 246). These trials were deemed not likely to meet the cut‑off date and excluded from the database if they met the following criteria: (1) pos‑
sessed a completion date before January 2012 (n = 112); (2) had completed, terminated or withdrawn status and their records were last verified 
before January 2012 (n = 37); (3) were not verified by the sponsor in more than 10 years (n = 18); 4) possessed a start date before 1998 (n = 19); 
bTrials in mixed populations were also excluded. BC breast cancer
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Triple‑negative/BRCA‑positive
In TN/BRCA-positive disease, poly(ADP-ribose) poly-
merase (PARP) 1/2-inhibitors were the most studied 
class of drugs (n = 6, 30.0 %; Table 2) followed by anti-
angiogenics (n = 4, 20.0 %) and mTOR/PI3K/Akt-inhib-
itors (n = 3, 15.0 %). Mono-class trials (n = 19, 95.0 %; 
Fig.  3a) focused on PARP-inhibitors (n  =  6, 31.6  %), 
mTOR-inhibitors (n  =  3, 15.8  %) and anti-angiogenics 
(n  =  3, 15.8  %). Trials combining multiple classes of 
agents (n  =  1, 5.0  %; Fig.  3b) were less prevalent, with 
only one combining a c-met-inhibitor and an anti-angi-
ogenic agent.
Other
In other populations, anti-angiogenics remained a key 
area of research (n  =  33, 42.8  %; Table  2). Mono-class 
trials (n  =  65, 84.4  %; Fig.  3a) focused predominantly 
on anti-angiogenic agents (n =  32, 49.2  %), while some 
research explored mTOR-inhibitors (n  =  6, 9.2  %), 
HER2-inhibitors (n  =  3, 4.6  %), ET (n  =  3, 4.6  %), 
Fig. 2 Proportion of different a patient subsets, and b classes of investigational target‑directed agents in current or ongoing trials. HER2 human epi‑
dermal growth factor receptor 2, HR hormone receptor, mTOR mammalian target of rapamycin, PARP poly ADP ribose polymerase, PK protein kinase
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Table 2 Randomized trial characteristics by biological subtype of trial population and treatment setting




Triple‑negative or  
BRCA‑positive [n (%)]
Other or unselected  
[n (%)]
Total [n (%)]
Total, n (proportion by subtype, %) 79 (28.2) 104 (37.1) 20 (7.1) 77 (27.5) 280 (100.0)
Populations
 Target‑matched 68 (86.1) 50 (48.1) 1 (5.0) 7 (9.1) 126 (45.0)
 Non target‑matched 11 (13.9) 54 (51.9) 19 (95.0) 70 (90.9) 154 (55.0)
Investigational target‑directed classes
 HER2‑inhibitors 64 (81.0) 4 (3.8) 0 (0) 5 (6.5) 73 (26.1)
 Endocrine agents 0 (0) 47 (45.2) 1 (5.0) 4 (5.2) 52 (18.6)
 Anti‑angiogenics 5 (6.3) 7 (6.7) 4 (20.0) 33 (42.8) 49 (17.5)
 mTOR/PI3K/Akt pathway‑inhibitors 4 (5.1) 14 (13.5) 3 (15.0) 7 (9.1) 28 (10.0)
 Growth factor‑inhibitors 2 (2.5) 12 (11.5) 2 (10.0) 4 (5.2) 20 (7.1)
 Intracellular, non‑receptor PK‑inhibitors 0 (0) 12 (11.5) 1 (5.0) 5 (6.5) 18 (6.4)
 Immunotherapy/vaccines 4 (5.1) 0 (0) 0 (0) 6 (7.8) 10 (3.6)
 PARP1/2‑inhibitors 0 (0) 1 (1.0) 6 (30.0) 0 (0) 7 (2.5)
 Other 0 (0) 7 (6.7) 3 (15.0) 13 (16.9) 23 (8.2)
Types of target‑directed therapy
 Established 59 (74.7) 56 (53.8) 2 (10.0) 16 (20.8) 133 (47.5)
 Emergent 20 (25.3) 48 (46.2) 18 (90.0) 61 (79.2) 147 (52.5)
Therapeutic strategies
 Chemotherapy‑based regimens 64 (81.0) 13 (12.5) 18 (90.0) 69 (89.6) 164 (58.6)
 Non chemotherapy‑based regimens 15 (19.0) 91 (87.5) 2 (10.0) 8 (10.4) 116 (41.4)
 ET‑based regimens 6 (7.6) 95 (91.3) 1 (5.0) 11 (14.3) 113 (40.4)
 Non ET‑based regimens 73 (92.4) 9 (8.6) 19 (95.0) 66 (85.7) 167 (59.6)
 Peptide‑drug conjugates 6 (7.6) 0 (0) 1 (5.0) 1 (1.3) 8 (2.8)
 Mono‑class regimens 60 (75.9) 51 (49.0) 19 (95.0) 65 (84.4) 195 (69.6)
 Multi‑class regimens 19 (24.0) 53 (51.0) 1 (5.0) 12 (15.6) 85 (30.4)
Categories Neoadjuvant [n (%)] Adjuvant [n (%)] Advanced [n (%)] Total [n (%)]
Total [n (proportion by setting, %)] 68 (24.3) 66 (23.6) 146 (52.1) 280 (100.0)
Subtype
 HER2‑positive 25 (36.8) 19 (28.8) 35 (23.9) 79 (28.2)
 HR‑positive 17 (25.0) 29 (43.9) 58 (39.7) 104 (37.1)
 Triple‑negative or BRCA‑positive 7 (10.3) 3 (4.5) 10 (6.8) 20 (7.1)
 Other or unselected 19 (27.9) 15 (22.7) 43 (29.4) 77 (27.5)
Primary endpoint
 Overall survival 0 (0) 1 (1.5) 6 (4.1) 7 (2.5)
 Quality of life 0 (0) 2 (3.0) 1 (0.7) 3 (1.1)
 Pathological complete response 36 (52.9) 0 (0) 0 (0) 36 (12.8)
 DFS/RFS/PFS/EFS 3 (4.4) 51 (77.3) 106 (72.6) 160 (57.1)
 Clinical response 15 (22.0) 1 (1.5) 19 (13.0) 35 (12.5)
 Biomarker 10 (14.7) 6 (9.1) 2 (1.4) 18 (6.4)
 Safety and tolerability 4 (5.9) 3 (4.5) 8 (5.5) 15 (5.4)
 Other 0 (0) 2 (3.0) 4 (2.7) 6 (2.1)
Study Phase
 Phase II (%) 53 (77.9) 15 (22.7) 96 (65.8) 164 (58.6)
 Phase III (%) 15 (22.0) 51 (77.3) 50 (34.2) 116 (41.4)
DFS disease-free survival, EFS event-free survival, ET endocrine therapy, HER2 human epidermal growth factor receptor 2, HR hormone receptor, mTOR mammalian 
target of rapamycin, PARP poly(ADP-ribose) polymerase, PI3K phosphoinositide 3-kinase, PFS progression-free survival, RFS relapse-free survival
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Fig. 3 Flowchart of trials with a one or b multiple classes of target‑directed agents in the investigational arm. aOne of the standard therapy options 
possible. In early (adjuvant and/or neoadjuvant) trials, standard therapy (including ET) may have been required before, during or after the investi‑
gational treatment and either before or after surgery. bTrials of HER2 vaccines that included patients with high levels (overexpression) of HER2 (in 
addition to patients with low and intermediate HER2 levels) were categorized under “HER2‑positive” while those that did not include patients overex‑
pressing HER2 were categorized under “Other”. Note: When present, non‑T‑D (including chemotherapy) agents were omitted from the investigational 
regimen short description. AA anti‑angiogenic, AMPKi AMPK inhibitor, ASCI Antigen‑Specific Cancer Immunotherapeutic, Bisph bisphosphonates, 
BRCA + BRCA‑positive, CDK4/6i cyclin‑dependent kinase 4/6 inhibitor, c‑KITi c‑KIT (and BCR/Abl and Src or PDGFR) inhibitor, dual T‑D experimental 
regimens containing two target‑directed agents, EGFRi epidermal growth factor receptor inhibitor, ET endocrine therapy, FGFRi fibroblast growth 
factor receptor inhibitor, FPTi farnesyl protein transferase inhibitor, GpNMB glycoprotein NMB, HDACi histone deacetylase inhibitor, HER2 + human 
epidermal growth factor receptor‑positive, HER2i human epidermal growth factor receptor inhibitor, HR + hormone receptor‑positive, Hsp90i, heat 
shock protein 90 inhibitor, IAPi inhibitor of apoptosis inhibitor, IDOi IDO pathway inhibitor, IGF(R)i insulin growth factor (receptor) inhibitor, MEK/
MAPK/ERKi MEK or MAPK/ERK inhibitor, mono‑class experimental regimens containing only one class of target‑directed agents, mTORi mammalian 
target of rapamycin pathway inhibitor, multi‑class experimental regimens containing more than one class of target‑directed agents, PARPi poly(ADP‑
ribose) polymerase inhibitor, PI3Ki phosphoinositide 3‑kinase inhibitor, Smo smoothened, SRCi SRC kinase family inhibitor, T‑D target‑directed 
therapy, TN triple‑negative
Fig. 4 Frequency of neoadjuvant, adjuvant and advanced studies in trials with primary completion date of a 2007–2011 or b 2012–2016
bisphosphonates (n =  3, 4.6  %), and metformin (n =  3, 
4.6 %). Some multi-class research was ongoing (n = 12, 
15.6  %; Fig.  3b), specifically combining bone-directed 
therapy and ET (n = 3, 25 %). Trials of HER2-inhibitors 
and/or vaccines were also conducted in HER2-negative 
patients (n = 6), including those with low or intermedi-
ate levels of HER2 and/or with HER2-expressing dissemi-
nated tumor cells.
Setting, primary end‑points and trial design
The majority of ongoing target-directed research was 
conducted in the advanced setting (n  =  146, 52.1  %), 
with fewer studies in the neo-adjuvant (n = 68, 24.3 %) 
and adjuvant (n = 66, 23.6 %) settings (Table 2). In the 
neo-adjuvant setting, most research was conducted 
in HER2-positive disease (n =  25, 36.8  %), while only 
10.3  % (n  =  7) was conducted in TN/BRCA-posi-
tive populations. Both the total number and propor-
tion of trials conducted in the neo-adjuvant setting in 
the 5-year period beginning January 2012 increased 
compared with those of the preceding 5-year period 
(2007–2011, n  =  25, 16.6  % vs 2012–2016, n  =  58, 
24.6 %; Fig. 4). The majority of trials in the adjuvant and 
advanced settings involved HR-positive (n = 29, 43.9 % 
and n =  58, 39.7  %, respectively; Table  2) and HER2-
positive populations (n = 19, 28.8 % and n = 35, 23.9 %, 
respectively).
The primary end-points used in targeted trials var-
ied by setting (Table 2). In the neo-adjuvant setting, the 
most common end-points were pathological complete 
response (pCR; n = 36, 52.9 %), clinical response (n = 15, 
22.0  %) and biomarker measurement (n  =  10, 14.7  %). 
In the adjuvant and advanced settings, time-to-event 
end-points were common (77.3 and 72.6 %, respectively) 
while the use of overall survival as a primary end-point in 
any setting was rare (1.5 and 4.1 %, respectively).
There was a slightly greater proportion of phase II trials 
compared with phase III trials overall (n = 164, 58.6 %; 
Table 2). Phase II trials were most common in the neo-
adjuvant (n = 53, 77.9 %) and advanced (n = 96, 65.8 %) 
settings, while phase III trials were more common in the 
adjuvant setting (n = 51, 77.3 %).
Discussion
Populations
Given the prevalence of expression and demonstrated 
ability to target HER2 and HRs, the proportion of 
research dedicated to populations defined by these 
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biomarkers is appropriate. However, relative to the over-
all incidence of HR-positive and TN disease (~75 % (Lim 
et  al. 2012; Anderson et  al. 2011; Nadji et  al. 2005) and 
~15  % (Foulkes et  al. 2010)), the amount clinical devel-
opment in these settings is low and highlights a need for 
further research in these settings.
Elimination of chemotherapy
One of the great promises of targeted therapy was the 
potential to reduce or eliminate the need for chemo-
therapy and its indiscriminate effect on normal tis-
sue. However, after more than a decade of research, the 
majority of trials conducted in non-HR-positive popu-
lations (n =  151, 85.8  %) combine targeted agents with 
chemotherapy. It is only recently that trials have begun to 
explore the removal of chemotherapy from targeted regi-
mens for select populations; e.g., eliminating chemother-
apy from HER2-directed regimens in elderly adjuvant 
patients (n =  1) or from dual HER2-targeted combina-
tions in the advanced and neo-adjuvant settings (n = 2).
Recurrence scores based on clinicopathological fea-
tures [e.g., Nottingham Prognostic Index (Blamey et  al. 
2007), Adjuvant! (Ravdin et  al. 2001), and PREDICT 
(Wishart et  al. 2011)] have also been useful in identify-
ing patients who may forego adjuvant chemotherapy. 
Gene signature-based scores are now being validated in 
randomized phase III trials in intermediate-risk, HR-
positive patients (TAILORx (ClinicalTrials.gov 2014a), 
RxPONDER (ClinicalTrials.gov 2014d), and MINDACT 
(ClinicalTrials.gov 2013)), and are expected to further 
define subsets of patients who may be spared the toxic-
ity of chemotherapy (Viale et  al. 2014; Bogaerts et  al. 
2006). Antibody-cytotoxic conjugates are yet another 
important means by which chemotherapy-associated 
adverse effects can be reduced. In HER2-positive dis-
ease, a HER2-directed cytotoxic is replacing existing 
single-agent targeted therapy or cytotoxic-targeted com-
binations, and a GpNMB-directed cytotoxic is being 
developed for GpNMB-expressing TN disease (METRIC 
trial, NCT01997333) (Celldex Therapeutics 2012; Clini-
calTrials.gov 2012, 2014c).
Combinatorial strategies
Effectively targeting oncogenic mutations or copy num-
ber alterations has proven challenging, with no new 
agents identified in the last 15  years. In this context, 
combinatorial approaches have become one of the most 
commonly explored strategies. In HER2-positive dis-
ease, mono-class regimens combining multiple targeted 
agents to more effectively block a given receptor have 
become the focus of ongoing combinatorial research. 
Dual-HER2-inhibition has held much promise in both 
the advanced (Baselga et  al. 2012c; Verma et  al. 2012) 
and neo-adjuvant (Gianni et  al. 2012) settings, yet find-
ings from the ALTTO trial, showing a lack of improve-
ment with the addition of lapatinib to standard adjuvant 
targeted therapy, calls into question the benefits of this 
approach in earlier settings (Piccart-Gebhart et al. 2014). 
Results from the APHINITY trial (NCT01358877), 
assessing the addition of pertuzumab (rather than lapa-
tinib) to adjuvant targeted therapy, will help clarify the 
role for combinatorial strategies in early disease.
In HR-positive disease, a main direction of research 
has been the development of multi-class regimens to 
inhibit secondary processes, such as treatment resistance 
(mTOR/PI3K-inhibitors; insulin growth factor recep-
tor [IGF(R)]-inhibitors; epidermal growth factor recep-
tor [EGFR]-inhibitors; fibroblast growth factor receptor 
[FGFR]-inhibitors), cell cycle regulation (CDK4/6-inhib-
itors) or effects of the tumor micro-environment (bis-
phosphonates). Breakthroughs such as the addition of the 
mTOR-inhibitor everolimus to exemestane in advanced 
BC resistant to prior non-steroidal aromatase-inhibitor 
therapy (Baselga et al. 2012b) and the addition of palboci-
clib to fulvestrant in patients with advanced BC progress-
ing on prior ET therapy (Turner et  al. 2015) illustrate 
the promise of combinatorial approaches in enhancing 
established targeted strategies. However, questions of tol-
erability and cost remain as combinatorial strategies are 
undertaken to more completely inhibit pro-oncogenic 
pathways.
Neo‑adjuvant setting: platform for accelerated drug 
development
The neo-adjuvant setting provides a unique platform 
for targeted agent research, with opportunities for cor-
relative studies and the potential for translating discov-
ery into benefit in the adjuvant setting. Relative to drug 
development, improvements in pCR have been correlated 
with survival outcomes in HER2-positive and TN sub-
types (Cortazar et al. 2014) and can be used as the basis 
for accelerated FDA approval (Prowell and Pazdur 2012). 
Although the FDA approved pertuzumab in the neoad-
juvant setting, the results of the Neosphere trial did not 
show a statistically significant association between pCR 
and 3-year disease-free survival and progression-free 
survival (PFS) (Gianni et al. 2015). The increase in both 
number and proportion of clinical trials conducted in this 
setting over the last several years suggests an increased 
commitment to neo-adjuvant research, although data 
also suggests that it remains an underutilized strategy.
The negative results of the ALTTO study (Piccart-
Gebhart et al. 2014), evaluating an adjuvant dual-HER2-
blockade, bring into question the assumption that benefits 
in the neo-adjuvant setting (Piccart-Gebhart et  al. 2013) 
automatically translate into adjuvant benefits. These 
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findings underscore the complexity and challenges of 
accelerated drug development. Innovative approaches to 
neo-adjuvant research, using adaptive Bayesian designs 
and pCR as the primary end-point, to rapidly select active 
novel agents (e.g., ISPY2 trial (ClinicalTrials.gov 2015)), 
may lead to more efficient use of research resources by 
requiring fewer patients, although absolute magnitudes of 
benefit are difficult to assess using this type of approach 
and results require phase III confirmation.
Optimization of research resources
Although BC is the most investigated disease site (Hirsch 
et al. 2013), it is also an area of research associated with one 
of the highest rates of drug attrition and trial failure (Begley 
and Ellis 2012; Hutchinson and Kirk 2011). Presently, anti-
angiogenic agent trials (n = 49, 17.5 %) comprise almost a 
fifth of all ongoing research, and the total number of these 
trials is comparable the sum of all ET directed research 
(n = 52, 18.6 %). Clinical testing of anti-angiogenics in BC 
has been marked by failure to demonstrate clinically sig-
nificant PFS and survival benefits and an increased risk of 
serious side effects (Miles et  al. 2010; Robert et  al. 2011; 
Hamburg 2011; Barrios et  al. 2010; Baselga et  al. 2012d; 
Mackey et al. 2013). Despite this, as of September 2013, a 
total of 25,784 patients were accrued to current anti-angi-
ogenic trials, with planned accrual of an additional 3833 
patients across 12 trials. A 2006 survey of leading devel-
opers estimates that the cost of enrolling a patient into a 
phase III trial is $26,000 (lifesciences world 2006; Stewart 
et  al. 2010). Given these figures, the investment directed 
toward anti-angiogenic research has amounted to a stag-
gering $770,042,000. As the hope of success continues to 
entice patients and clinicians alike to fully explore the ben-
efits of a given class of therapy, prudence would call for a 
redirection of resources towards classes of agents that have 
demonstrated therapeutic benefit or for which a biomarker 
is available to guide therapy. This is best exemplified in 
the recent discovery of the 14-gene signature to identify 
immune-enriched patients who preferentially respond to 
trastuzumab therapy (Perez et al. 2014).
Conclusions
Target-directed research is essential to ongoing research 
efforts in BC and our understanding of how to optimize 
these strategies continues to evolve. Our findings sug-
gest that there is a continued need for target-matched 
agent development, maintenance of a value-based focus 
in research and a need for the clinical development of 
agents to treat TN/BRCA-positive and HR-positive BC.
Methods
Target‑directed trial dataset
A search of the CT.gov website was conducted on Sep-
tember 4, 2013 to identify randomized phase II and III 
trials of targeted therapies in BC. We considered tar-
geted therapies to be anti-cancer drugs with a clear cel-
lular or molecularly-directed mechanisms of action that 
interfere with cell growth signaling or tumor blood ves-
sel development, promote death of specific cell types, 
or stimulate the immune system to destroy specific cell 
types and/or deliver toxic drugs to cancer cells (National 
Cancer Institute 2014). All non-randomized, non-sys-
temic, non-therapeutic, or withdrawn trials, as well as 
those conducted in a non-invasive setting, without a 
target-directed agent in the experimental arm, or with a 
primary completion date (date of primary outcome data 
collection, or date expected) before January 2012, were 
excluded.
Trial review and classification
Each trial was classified and analyzed based on the fol-
lowing 9 criteria, which were established based on the 
record title: (1) degree to which the investigational tar-
geted agent is established (defined below), (2) number 
and (3) class of targeted agents in the investigational 
arm, (4) use of continued targeted therapy, (5) setting, 
(6) biological subtype of population, (7) status of trial, 
(8) study type and (9) end-points used. If the category 
was unclear, conditions and key words were assessed or 
the full CT.gov record was reviewed.
Established targeted-drugs, defined as those with at 
least one US Food and Drug Administration (FDA)-
approved BC indication as of September 4, 2013, are 
summarized in Table  3. Bone-modifying/remodeling 
agents and progesterone were considered established 
due to their historical and widespread use in BC treat-
ment; all other agents were defined as emergent. Tri-
als were categorized into 4 mutually exclusive groups 
based on the biomarker status of the trial population, 
in order of therapeutic relevance, as follows: HER2-
positive; HR-positive; TN or BRCA-mutated; (TN/
BRCA-positive); and other populations (HER2-nega-
tive trials with HR status unspecified; other subtypes 
and unselected; not defined by biomarker status).
To assess the degree to which neo-adjuvant trials have 
changed over the last 5  years, trials with primary com-
pletion dates between 2012 and 2016 were compared to 
those with primary completion dates between 2007 and 
2011.
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